Detecting and understanding genetic and structural features in HIV-1 B subtype V3 underlying HIV-1 co-receptor usage

MOTIVATION To define V3 genetic elements and structural features underlying different HIV-1 co-receptor usage in vivo. RESULTS By probabilistically modeling mutations in the viruses isolated from HIV-1 B subtype patients, we present a unique statistical procedure that would first identify V3 determinants associated with the usage of different co-receptors cooperatively or independently, and then delineate the complicated interactions among mutations functioning cooperatively. We built a model based on dual usage of CXCR4 and CCR5 co-receptors. The molecular basis of our statistical predictions is further confirmed by phenotypic and molecular modeling analyses. Our results provide new insights on molecular basis of different HIV-1 co-receptor usage. This is critical to optimize the use of genotypic tropism testing in clinical practice and to obtain molecular-implication for design of vaccine and new entry-inhibitors.

[1]  J. Mullins,et al.  HIV Sequence Compendium 2010 , 2010 .

[2]  J. Albert,et al.  Coreceptor usage of primary human immunodeficiency virus type 1 isolates varies according to biological phenotype , 1997, Journal of virology.

[3]  S. Zolla-Pazner,et al.  Structural basis for coreceptor selectivity by the HIV type 1 V3 loop. , 2007, AIDS research and human retroviruses.

[4]  W. L. Jorgensen,et al.  Development and Testing of the OPLS All-Atom Force Field on Conformational Energetics and Properties of Organic Liquids , 1996 .

[5]  Paolo Piazza,et al.  Emergence and persistence of CXCR4-tropic HIV-1 in a population of men from the multicenter AIDS cohort study. , 2008, The Journal of infectious diseases.

[6]  L. Ratner,et al.  Human Immunodeficiency Virus Type 1 Coreceptor Switching: V1/V2 Gain-of-Fitness Mutations Compensate for V3 Loss-of-Fitness Mutations , 2006, Journal of Virology.

[7]  Dominique Schols,et al.  HIV chemokine receptor inhibitors as novel anti-HIV drugs. , 2005, Cytokine & growth factor reviews.

[8]  Donald E. Mosier,et al.  Evolution of CXCR4-Using Human Immunodeficiency Virus Type 1 SF162 Is Associated with Two Unique Envelope Mutations , 2007, Journal of Virology.

[9]  G. Chang,et al.  Macromodel—an integrated software system for modeling organic and bioorganic molecules using molecular mechanics , 1990 .

[10]  Barbara Horner-Miller,et al.  Proceedings of the 2006 ACM/IEEE conference on Supercomputing , 2006 .

[11]  Bette Korber,et al.  Structure of a V3-Containing HIV-1 gp120 Core , 2005, Science.

[12]  Anna Artese,et al.  Key genetic elements in HIV-1 gp120 V1,V2 and C4 domains tightly and differentially modulate gp120 interaction with the CCR5 and CXCR4 N terminus and HIV-1 antigenetic Potential , 2011 .

[13]  D. M. Ryan,et al.  Rational design of potent sialidase-based inhibitors of influenza virus replication , 1993, Nature.

[14]  E. Fenyö,et al.  In vivo evolution of HIV-1 co-receptor usage and sensitivity to chemokine-mediated suppression , 1997, Nature Medicine.

[15]  Sebastian Bonhoeffer,et al.  The HIV coreceptor switch: a population dynamical perspective. , 2005, Trends in microbiology.

[16]  B. Korber,et al.  A new classification for HIV-1 , 1998, Nature.

[17]  Valentina Svicher,et al.  392 SPECIFIC HBSAG GENETIC-DETERMINANTS ARE ASSOCIATED WITH OCCULT HBV-INFECTION IN VIVO AND HBSAG-DETECTION , 2011 .

[18]  Stefano Alcaro,et al.  GBPM: GRID-based pharmacophore model: concept and application studies to protein-protein recognition , 2006, Bioinform..

[19]  Stefano Alcaro,et al.  Computational analysis of Human Immunodeficiency Virus (HIV) Type-1 reverse transcriptase crystallographic models based on significant conserved residues found in Highly Active Antiretroviral Therapy (HAART)-treated patients. , 2010, Current medicinal chemistry.

[20]  Arthur J. Olson,et al.  AutoDock Vina: Improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading , 2009, J. Comput. Chem..

[21]  P. Goodford.  A computational procedure for determining energetically favorable binding sites on biologically important macromolecules. , 1985, Journal of medicinal chemistry.

[22]  W. Delano.  The PyMOL Molecular Graphics System , 2002 .

[23]  W. C. Still,et al.  Semianalytical treatment of solvation for molecular mechanics and dynamics , 1990 .

[24]  Xiao Yang,et al.  Systematic Investigation on Interactions for HIV Drug Resistance and Cross-Resistance among Protease Inhibitors , 2012 .

[25]  Anna Urbańska,et al.  Analysis of V3 loop sequences using various bioinformatic tools designed for genotypic HIV-1 tropism testing , 2010 .

[26]  Stefano Alcaro,et al.  Identification and Structural Characterization of Novel Genetic Elements in the HIV-1 V3 Loop Regulating Coreceptor Usage , 2011, Antiviral therapy.

[27]  W. Clark Still,et al.  AMBER torsional parameters for the peptide backbone , 1992 .

[28]  Jeroen Aerssens,et al.  HIV-1 dual/mixed tropic isolates show different genetic and phenotypic characteristics and response to maraviroc in vitro. , 2011, Antiviral research.

[29]  B. Korber,et al.  HIV sequence compendium 2002 , 2002 .

[30]  David A. Price,et al.  Maraviroc (UK-427,857), a Potent, Orally Bioavailable, and Selective Small-Molecule Inhibitor of Chemokine Receptor CCR5 with Broad-Spectrum Anti-Human Immunodeficiency Virus Type 1 Activity , 2005, Antimicrobial Agents and Chemotherapy.

[31]  Christoph Seibert,et al.  Structural Basis of CXCR4 Sulfotyrosine Recognition by the Chemokine SDF-1/CXCL12 , 2008, Science Signaling.

[32]  B. Cullen,et al.  Identification of the envelope V3 loop as the primary determinant of cell tropism in HIV-1. , 1991, Science.

[33]  Pascale Briand,et al.  Determination of Essential Amino Acids Involved in the CD4-Independent Tropism of the X4 Human Immunodeficiency Virus Type 1 m7NDK Isolate: Role of Potential N Glycosylations in the C2 and V3 Regions of gp120 , 2001, Journal of Virology.

[34]  Thomas Lengauer,et al.  Structural Descriptors of gp120 V3 Loop for the Prediction of HIV-1 Coreceptor Usage , 2007, PLoS Comput. Biol..

[35]  Wei Huang,et al.  HIV-1 tropism and survival in vertically infected Ugandan infants. , 2008, The Journal of infectious diseases.

[36]  A. Cann,et al.  The region of the envelope gene of human immunodeficiency virus type 1 responsible for determination of cell tropism , 1992, Journal of virology.

[37]  Peter D. Kwong,et al.  Structures of the CCR5 N Terminus and of a Tyrosine-Sulfated Antibody with HIV-1 gp120 and CD4 , 2007, Science.

[38]  R. Friesner,et al.  Evaluation and Reparametrization of the OPLS-AA Force Field for Proteins via Comparison with Accurate Quantum Chemical Calculations on Peptides† , 2001 .

[39]  R. Lihana,et al.  HIV-1 subtype and viral tropism determination for evaluating antiretroviral therapy options: an analysis of archived Kenyan blood samples , 2009, BMC infectious diseases.

[40]  Wei Huang,et al.  Coreceptor Tropism in Human Immunodeficiency Virus Type 1 Subtype D: High Prevalence of CXCR4 Tropism and Heterogeneous Composition of Viral Populations , 2007, Journal of Virology.

[41]  T L Hoffman,et al.  HIV-1 envelope determinants for cell tropism and chemokine receptor use. , 1999, Molecular membrane biology.

[42]  B. Clotet,et al.  Prevalence of CCR5-tropic HIV-1 Among Treatment-Experienced Individuals in Spain , 2009, HIV clinical trials.

[43]  J. Gasteiger,et al.  ITERATIVE PARTIAL EQUALIZATION OF ORBITAL ELECTRONEGATIVITY – A RAPID ACCESS TO ATOMIC CHARGES , 1980 .

[44]  J. Binley,et al.  Virus Entry via the Alternative Coreceptors CCR3 and FPRL1 Differs by Human Immunodeficiency Virus Type 1 Subtype , 2009, Journal of Virology.

[45]  B. Chesebro,et al.  Mapping of independent V3 envelope determinants of human immunodeficiency virus type 1 macrophage tropism and syncytium formation in lymphocytes , 1996, Journal of virology.

[46]  Anna Artese,et al.  Signature mutations in V3 and bridging sheet domain of HIV-1 gp120 are specifically associated with dual tropism and modulate the interaction with CCR5 N-terminus , 2011 .

[47]  Jing Zhang,et al.  Detecting and understanding combinatorial mutation patterns responsible for HIV drug resistance , 2010, Proceedings of the National Academy of Sciences.

[48]  Miriam K. Konkel,et al.  The Orphan Seven-Transmembrane Receptor Apj Supports the Entry of Primary T-Cell-Line-Tropic and Dualtropic Human Immunodeficiency Virus Type 1 , 1998, Journal of Virology.

[49]  C. Cheng‐Mayer,et al.  Amino acid substitutions in the V3 loop are responsible for adaptation to growth in transformed T-cell lines of a primary human immunodeficiency virus type 1. , 1995, Virology.

[50]  Valentina Svicher,et al.  Novel HBsAg markers tightly correlate with occult HBV infection and strongly affect HBsAg detection. , 2012, Antiviral research.

[51]  R. Connor,et al.  Change in Coreceptor Use Correlates with Disease Progression in HIV-1–Infected Individuals , 1997, The Journal of experimental medicine.

[52]  Stefano Alcaro,et al.  Rational Design, Synthesis, Biophysical and Antiproliferative Evaluation of Fluorenone Derivatives with DNA G‐Quadruplex Binding Properties , 2010, ChemMedChem.

[53]  Dan R. Littman,et al.  Use of Coreceptors Other Than CCR5 by Non-Syncytium-Inducing Adult and Pediatric Isolates of Human Immunodeficiency Virus Type 1 Is Rare In Vitro , 1998, Journal of Virology.